Research Progress of BRAF Fusion in Non-small Cell Lung Cancer
| Autor: | Ping XIAO, Diansheng ZHONG |
|---|---|
| Jazyk: | čínština |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Chinese Journal of Lung Cancer, Vol 26, Iss 10, Pp 782-788 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1009-3419 1999-6187 |
| DOI: | 10.3779/j.issn.1009-3419.2023.101.28 |
| Popis: | In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to mutations, BRAF fusion can also occur. With the development of gene detection, the detection of BRAF fusion is gradually increasing, but there is a lack of effective therapeutic strategies for BRAF fusion. In this paper, we review the clinical characteristics, mechanism of action, and clinical treatment of BRAF fusion to provide a basis for the treatment of BRAF fusion in NSCLC patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|